Andy M. Trotti, MD

BOARD CERTIFICATION:
          •  Radiation Oncology

FELLOWSHIP:

RESIDENCY:
          •  University of Alabama at Birmingham - Radiation Oncology

MEDICAL SCHOOL:
          •  University of Florida - MD

• Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar;31(7):845-852. Pubmedid: 23182993. Pmcid: PMC3577950.


• May JT, Rao N, Sabater RD, Boutrid H, Caudell JJ, Merchant F, Han G, Padhya TA, McCaffrey JC, Tanvetyanon T, Deconti R, Kish J, McCaffrey TV, Trotti A. Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma. Head Neck. 2013 Mar. Pubmedid: 23468387.


• Gillison ML, Zhang Q, Jordan R, Xiao W, Westra WH, Trotti A, Spencer S, Harris J, Chung CH, Ang KK. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol. 2012 Aug;30(17):2102-2111. Pubmedid: 22565003. Pmcid: PMC3397696.


• Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf G, Worden F. Mucosal melanoma of the head and neck. J Natl Compr Canc Netw. 2012 Mar;10(3):320-338. Pubmedid: 22393194.


• Chung CH, Zhang Q, Hammond EM, Trotti AM, Wang H, Spencer S, Zhang HZ, Cooper J, Jordan R, Rotman MH, Ang KK. Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2011 Oct;81(2):331-338. Pubmedid: 20732768. Pmcid: PMC2992592.


• Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf GT, Worden F. Head and neck cancers. J Natl Compr Canc Netw. 2011 Jun;9(6):596-650. Pubmedid: 21636536.


• Chung CH, Dignam JJ, Hammond ME, Klimowicz AC, Petrillo SK, Magliocco A, Jordan R, Trotti A, Spencer S, Cooper JS, Le QT, Ang KK. Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol. 2011 May;29(10):1326-1334. Pubmedid: 21357786. Pmcid: PMC3084000.


• Trotti A, Eisbruch A. Reducing xerostomia through advanced technology. Lancet Oncol. 2011 Feb;12(2):110-111. Pubmedid: 21277541.


• Rao NG, Yu HH, Trotti A, Sondak VK. The role of radiation therapy in the management of cutaneous melanoma. Surg Oncol Clin N Am. 2011 Jan;20(1):115-131. Pubmedid: 21111962.


• Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol. 2010 Jun;28(18):2996-3001. Pubmedid: 20479390.


• Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010 Jun;28(18):2989-2995. Pubmedid: 20479425.


• Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010 Apr;18(4):509-522. Pubmedid: 20145956.


• Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D'Souza G, Gravitt PE, Westra W, Psyrri A, Martin Kast W, Koutsky LA, Giuliano A, Krosnick S, Trotti A, Schuller DE, Forastiere A, Dansky Ullmann C. Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck. 2009 Nov;31(11):1393-1422. Pubmedid: 19787782.


• Salama JK, Haddad RI, Kies MS, Busse PM, Dong L, Brizel DM, Eisbruch A, Tishler RB, Trotti AM, Garden AS. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009 Nov;75(3):725-733. Pubmedid: 19362781.


• Murphy BA, Beaumont JL, Isitt J, Garden AS, Gwede CK, Trotti AM, Meredith RF, Epstein JB, Le QT, Brizel DM, Bellm LA, Wells N, Cella D. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage. 2009 Oct;38(4):522-532. Pubmedid: 19608377.


• Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol. 2009 Oct;27(28):4727-4732. Pubmedid: 19720915. Pmcid: PMC2754914.


• Le QT, Harris J, Magliocco AM, Kong CS, Diaz R, Shin B, Cao H, Trotti A, Erler JT, Chung CH, Dicker A, Pajak TF, Giaccia AJ, Ang KK. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol. 2009 Sep;27(26):4281-4286. Pubmedid: 19667273. Pmcid: PMC2744270.


• Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):687-692. Pubmedid: 19620591.


• Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, Deconti R, Trotti A. Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer. J Clin Oncol. 2009 Apr;27(12):1983-1991. Pubmedid: 19289616.


• Forastiere AA, Trotti AM. Searching for Less Toxic Larynx Preservation: A Need for Common Definitions and Metrics. J Natl Cancer Inst. 2009 Feb;101(3):129-131. Pubmedid: 19176460.


• Tanvetyanon T, Qin D, Padhya T, Kapoor R, McCaffrey J, Trotti A. Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis. Am J Otolaryngol. 2009 Jan;30(1):38-43. Pubmedid: 19027511.


• Hensley M, Hagerty K, Kewalramani T, Green D, Meropol N, Wasserman T, Cohen G, Emami B, Gradishar W, Mitchell R, Thigpen J, Trotti A, von HoffD, Schuchter L. American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants. J Clin Oncol. 2009 Jan;27(1):127-145. Pubmedid: 19018081.


• Garden AS, Harris J, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS, Ang KK. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys. 2008 Aug;71(5):1351-1355. Pubmedid: 18640496. Pmcid: PMC2582390.


• Machtay M, Moughan J, Trotti A, Garden A, Weber R, Cooper J, Forastiere A, Ang K. Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis. J Clin Oncol. 2008 Jul;26(21):3582-3589. Pubmedid: 18559875.


• Trotti A, Pajak TF, Ridge JA. Treatment of head and neck cancer. N Engl J Med. 2008 Mar;358(10):1076. Pubmedid: 18326079.


• Bensinger W, Schubert M, Ang K, Brizel D, Brown E, Eilers J, Elting L, Mittal B, Schattner M, Spielberger R, Treister N, Trotti AM 3rd. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008 Jan;6:S1-S21. Pubmedid: 18289497.


• Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007 Nov;25(32):5121-5127. Pubmedid: 17991931.


• Calvin D, Hammond M, Pajak T, Trotti A, Meredith R, Rotman M, Jones C, Byhardt R, Demas W, Ang K, Fu K. Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial. Am J Clin Oncol. 2007 Aug;30(4):406-419. Pubmedid: 17762442.


• Trotti A, Pajak T, Gwede C, Paulus R, Cooper J, Forastiere A, Ridge J, Watkins-Bruner D, Garden A, Ang K, Curran W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007 Jul;8(7):613-624. Pubmedid: 17543584.


• Forastiere A, Trotti A, Pfister D, Grandis J. Head and neck cancer: recent advances and new standards of care. J Clin Oncol. 2006 Jun;24(17):2603-2605. Pubmedid: 16763271.


• Chen Y, Trotti A, Coleman C, Machtay M, Mirimanoff R, Hay J, O'brien P, El-Gueddari B, Salvajoli J, Jeremic B. Adverse event reporting and developments in radiation biology after normaltissue injury: International Atomic Energy Agency consultation. Int J Radiat Oncol Biol Phys. 2006 Apr;64(5):1442-51. Epub 2. Pubmedid: 16414207.


• Wood G, Casey L, Trotti A. Skin changes. Cancer Treat Res. 2006;128:171-181. Pubmedid: 16335018.


• Ang K, Harris J, Garden A, Trotti A, Jones C, Carrascosa L, Cheng J, Spencer S, Forastiere A, Weber R. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol. 2005 May;23(13):3008-3015. Pubmedid: 15860857.


• Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B. Evaluation of new treatments in radiation oncology: are they better than standard treatments?. JAMA. 2005 Feb;293(8):970-978. Pubmedid: 15728168. Pmcid: PMC1779758.


• Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, Pajak TF, Fleming TR, Henke M, Bourhis J, Rosenthal DI, Junor E, Cmelak A, Sheehan F, Pulliam J, Devitt-Risse P, Fuchs H, Chambers M, O'Sullivan B, Ang KK. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys. 2004 Mar;58(3):674-681. Pubmedid: 14967419.


• Trotti A, Bentzen S. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol. 2004;22:19-22. Pubmedid: 14657230.


• Trotti A, Bellm L, Epstein J, Frame D, Fuchs H, Gwede C, Komaroff E, Nalysnyk L, Zilberberg M. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253-262. Pubmedid: 12742264.


• Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman C, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-181. Pubmedid: 12903007.


• Rose-Ped A, Bellm L, Epstein J, Trotti A, Gwede C, Fuch H. Complications of radiation therapy for head and neck cancer. The patient's perspective. Cancer Nurs. 2002;25(6):461-467. Pubmedid: 12464838.


• Gwede C, Johnson D, Daniels S, Trotti A. Assessment of toxicity in cooperative oncology clinical trials: the long and short of it. J Oncol Manag. 2002;11(2):15-21. Pubmedid: 11989815.


• Trotti A. The evolution and application of toxicity criteria. Semin Radiat Oncol. 2002;12(1):1-3. Pubmedid: 11917276.


• Kim C, Yeatman T, Coppola D, Trotti A, Williams B, Barthel J, Dinwoodie W, Karl R, Marcet J. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg. 2001 Sep;234(3):352-358. Pubmedid: 11524588. Pmcid: PMC1422026.


• Smith D, Messina J, Perrott R, Berman C, Reintgen D, Cruse C, Glass F, DeConti R, Trotti A, Fenske N. Clinical approach to neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Cancer Control. 2000;7(1):72-83. Pubmedid: 10740663.


• Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormic B, Morris M, Rich T, Shipley W, Curran W. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):13-47. Pubmedid: 10758303.


• Fu K, Pajak T, Trotti A, Jones C, Spencer S, Phillips T, Garden A, Ridge J, Cooper J, Ang K. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation to two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7-16. Pubmedid: 10924966.


• Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000;47(1):1-12. Pubmedid: 10758302.


• Herskovic A, Scott C, Demas W, Gaspar L, Trotti A. Accelerated hyperfractionation for bronchogenic cancer: Radiation Therapy Oncology Group 9205. Am J Clin Oncol. 2000;23(2):207-212. Pubmedid: 10776986.


• Flood W, Lee D, Trotti A, Spencer S, Murphy B, Khuri F, DeConti R, Wheeler R, Forastiere A. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin. Semin Rad Oncol. 1999;9(2):61-69. Pubmedid: 10210542.


• Johnson D, Roberts C, Trotti, III A, Greenberg H. Professional satisfaction among radiation therapists: a regional survey. Radiation Therapist. 1998;7(1):103-110. Pubmedid: noPMID.


• Sekharam M, Trotti, III A, Cunnick J, Wu J. Supression of fibroblast cell cycle progression in G1 phase by N-acetylcysteine. Toxicol Appl Pharmacol. 1998;149:210-216. Pubmedid: 9571990.


• Trotti A, Johnson D, Gwede C, Casey L, Sauder B, Cantor A. Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI). Int J Radiat Oncol Biol Phys. 1998;42(2):257-261. Pubmedid: 9788402.


• Trotti, III A, Klotch D, Endicott J, Ridley M, Cantor A. Postoperative accelerated radiotherapy in high-risk squamous cell carcinoma of the head and neck: long-term results of a prospective trial. Head Neck. 1998;20(2):119-123. Pubmedid: 9484942.


• Futran N, Trotti, III A, Gwede C. Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations. Lancet. 1997;107(3):391-395. Pubmedid: 9121320.


• Balducci L, Trotti, III A. Organ preservation: an effective and safe form of cancer treatment. Clin Geriatr Med. 1997;13(1):185-201. Pubmedid: 8995107.


• Cruse C, Reintgen D, Glass F, Messina J, Trotti, III A, DeConti R. Clinical practice guidelines: neuroendocrine tumors of the skin. Cancer Control. 1997;4:258-260. Pubmedid: noPMID.


• Trotti, III A. Toxicity antagonists in cancer therapy. Curr Opin Oncol. 1997;9:569-578. Pubmedid: 9370079.


• Johnson D, Casey L, Gwede C, Friedland J, Trotti, III A. 1996;850-851.


• Vaidynathan M, Clarke L, Velthuizen R, Phuphanich S, Bensaid A, Hall L, Bezdek J, Greenberg H, Trotti, III A, Silbiger M. Comparison of supervised MRI segmentation methods for tumor volume determination during therapy. Magn Reson Imaging. 1995;13(5):719-728. Pubmedid: 8569446.


• Endicott J, Trotti III A. Organ preservation in patients with head and neck cancer. Cancer Control. 1994;1(1):13-19.


• Trotti III A, Klotch D, Endicott J, Ridley M, Greenberg H. A prospective trial of accelerated radiotherapy in the postoperative treatment of high risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1993;26(1):13-21. Pubmedid: 8482619.


• Gupta S, Spiers A, Saba H, Moscinski L, Lyman G, Diaz J, Trotti, III A, Ridley M, Endicott J, Sanderson R. Extranodal lymphomas of the head and neck (ELHN): A six-year survey. Blood. 1993;82:2245-2245.


• Trotti III A, Peters L. Role of radiotherapy in the primary management of mucosal melanoma of the head and neck. Semin Surg Oncol. 1992;9(3):246-250.


• Trotti III A, Peters L. The role of radiotherapy in the primary management of muscosal melanoma. Ann Plast Surg. 1992;28(1):39-44.

As one of the longest serving Moffitt physicians, Dr. Trotti is recognized for expertise in head and neck and cutaneous malignancies, and the adverse effects of cancer treatment. He has conducted original and collaborative group clinical trials in head and neck cancer at the Cancer Center for more than 17 years.

Under his leadership, Moffitt became a member of the National Cancer Institute-sponsored Radiation Therapy Oncology Group (RTOG) in 1990 and continues today as one of a select group of active full members. Dr. Trotti serves as institutional principal investigator for RTOG studies. Several of Dr.Trotti's original pilot studies conducted at Moffitt in the areas of fractionation, toxicity interventions, and combined modality therapy have advanced to become national multicenter trials. Dr. Trotti is co-chair of the RTOG Head and Neck Committee. Under his guidance, several of his radiation oncology colleagues at Moffitt have participated in leadership roles within RTOG, including the Quality of Life Committee, Outcomes Committee, Special Populations Committees, and Research Associates Committee. Dr. Zachariah and Dr. Gwede from Radiation Oncology are currently leading a phase III RTOG trial of octreotide in the prevention of radiation-induced diarrhea. As part of the effort to measure outcomes, Darlene Johnson, MBA, and Dr. Trotti developed and validated a radiation-specific quality of life tool currently in use in two national RTOG trials. Dr. Trotti and colleague Dr. Javier Torres-Roca were recently awarded a pilot grant to study genomic predictors of radiosensitivity in RTOG populations.

Dr. Trotti is co-chair of the Health Services Research (HSR) Committees for both the American Society of Therapeutic Radiology and Oncology (ASTRO) and the American Society of Clinical Oncology (ASCO). Dr. Trotti has a unique area of expertise: the recognition, reporting, prevention, and management of the adverse effects of cancer treatment. Dr Trotti assisted the NCI in creating the current NCI dictionary for adverse events (CTCAE). This document has become the international standard for toxicity reporting. He has also led pivotal trials testing iseganan and lisofylline in mucositis. Dr. Trotti is Co-PI of a multicenter phase III randomized trial testing KGF for the reduction of H&N mucositis, sponsored by Amgen and RTOG. Dr. Trotti and colleagues were awarded federal grants to develop electronic methods of grading and reporting toxicity in clinical trials (Safety Profiler).